Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the PD-L1 And PIK3CA Testing Market covering 2026–2035?
The pd-l1 and pik3ca testing market size has experienced substantial expansion in recent years. It is projected to increase from $1.67 billion in 2025 to $1.93 billion in 2026, at a compound annual growth rate (CAGR) of 15.5%. The historical growth of this market can be attributed to several key factors, including the development of pd-l1 and pik3ca assays, their increasing adoption in clinical trials, the growing prevalence of cancer, ongoing advancements in molecular diagnostics, and a heightened awareness of personalized therapy.
The pd-l1 and pik3ca testing market is poised for significant expansion in the coming years, with projections indicating it will reach $3.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.2%. This anticipated growth is largely driven by factors such as the integration of artificial intelligence in biomarker detection, the increasing application of liquid biopsies, the ongoing expansion of precision oncology, strategic partnerships formed between diagnostics and pharmaceutical companies, and regulatory approvals for next-generation assays. Key trends during this forecast period are expected to include targeted cancer biomarker testing, AI-based mutation analysis, broader adoption of liquid biopsy techniques, enhanced integration with drug development processes, and high-throughput genomic screening.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28289&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The PD-L1 And PIK3CA Testing Market?
The rising incidence of cancer is projected to drive expansion within the PD-L1 and PIK3CA testing market. Cancer is defined by the unchecked proliferation and dissemination of atypical cells throughout the body, capable of invading adjacent tissues and potentially spreading to distant sites. The widespread occurrence of cancer stems from escalating lifestyle-associated risks and an aging global populace, resulting in elevated diagnosis rates and an increased need for timely detection and potent therapeutic strategies. PD-L1 and PIK3CA testing plays a crucial role in cancer management by enabling precise diagnoses and facilitating the use of targeted therapies, thereby customizing treatment plans for individual patients and enhancing their clinical results. As an illustration, in September 2024, the American Cancer Society, a US-based non-profit organization, reported that global cancer cases in men are anticipated to increase by 84% by 2029, escalating from 10.3 million in 2022 to 19 million. Consequently, the rising prevalence of cancer is fueling the expansion of the PD-L1 and PIK3CA testing market.
What Segments Are Identified Within The Structure Of The PD-L1 And PIK3CA Testing Market?
The pd-l1 and pik3ca testing market covered in this report is segmented –
1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction
2) By Sample Type: Tissue Samples, Liquid Biopsy Samples
3) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications
4) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies
Subsegments:
1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis
2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing
3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction
How Are Emerging Trends Affecting The Progression Of The PD-L1 And PIK3CA Testing Market?
Major companies operating in the PD-L1 and PIK3CA testing market are increasingly concentrating on technological advancements, specifically companion diagnostic integration, to enhance therapeutic targeting, improve treatment efficacy, and support personalized medicine approaches in oncology. Companion diagnostic integration refers to sophisticated, technology-driven testing systems developed in conjunction with targeted medicines to identify patient populations most likely to benefit from specific treatments based on their unique biomarker profiles. For example, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, launched Itovebi (inavolisib) in combination with palbociclib and fulvestrant for adults diagnosed with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. This regimen received approval from the Food and Drug Administration (FDA), a US-based federal agency, following the pivotal Phase III INAVO120 study. The study revealed that the treatment more than doubled progression-free survival compared with palbociclib and fulvestrant alone. This marks Roche’s first targeted therapy for HR-positive disease and incorporates a companion diagnostic to identify eligible patients, signifying a considerable leap in precision medicine for a patient demographic facing limited first-line treatment options.
Which Major Firms Are Strengthening Their Position In The PD-L1 And PIK3CA Testing Market?
Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report
Which Global Regions Are Shaping The Competitive Landscape Of The PD-L1 And PIK3CA Testing Market?
North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized PD-L1 And PIK3CA Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28289&type=smp
Browse Through More Reports Similar to the Global PD-L1 And PIK3CA Testing Market 2026, By The Business Research Company
Hpv Testing And Pap Test Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report
D Dimer Testing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/d-dimer-testing-global-market-report
Direct To Consumer Dtc Laboratory Testing Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company